Advanced Imaging


Industry News

Updated: July 8th, 2008 05:26 PM CDT

OmniVision Image Sensor Powers Avantis FDA-Cleared 'Third Eye(TM)' Disposable Endoscope Accessory for Colonoscopy

via PRNewswire

Earlier this month, Avantis demonstrated the Third Eye Retroscope at the Annual Scientific Meeting of the American College of Gastroenterology in Philadelphia . Jacques Van Dam , MD, a member of the Avantis Scientific AdvisoryBoard and Director of Endoscopy at Stanford University, will present anabstract of a pilot study demonstrating the feasibility of the Third Eye Retroscope on October 31 during United European Gastroenterology Week in Paris .A larger multi-center study to further validate the efficacy of the device is currently in progress.

"Over 20 million colonoscopy procedures are performed every year in the United States and at least twice that many worldwide," said Bruce Weyer , VicePresident of Marketing at OmniVision. "We're excited about the potentialhealth and procedural benefits of single-use disposable cameras in a number of medical applications and anticipate steady growth in the medical market for our image sensors in future years."

About OmniVision(R)

OmniVision Technologies designs and markets high-performance semiconductor image sensors. Its OmniPixel(R), OmniPixel2(TM), OmniPixel3(TM) andCameraChip(TM) products are highly integrated single-chip CMOS image sensorsfor mass-market consumer and commercial applications such as mobile phones,digital still cameras, security and surveillance systems, interactive videogames, laptops and PCs and automotive and medical imaging systems. Additional information is available at

About Avantis Medical Systems, Inc.

Avantis Medical Systems, Inc. is a medical device company founded todevelop and manufacture catheter-based endoscopic devices. Based in Sunnyvale ,CA, the Company's initial focus is on devices for use in detecting andtreating cancers of the gastrointestinal (GI) tract. The Avantis team has manydecades of experience in the medical device industry, and focuses ondeveloping solutions for problems, hazards and inconveniences associated withtraditional technologies. The Company is developing an extensive portfolio ofproducts based on the convergent technologies of micro-chips and reinforcedcatheters. Additional information is available at

Safe-Harbor Language

Certain statements in this press release, including statements regardingthe performance and capabilities of and the anticipated demand for the OV6920CMOS image sensors are forward-looking statements that are subject to risksand uncertainties. These risks and uncertainties, which could cause theforward-looking statements and OmniVision's results to differ materially,include, without limitation: potential errors, design flaws or other problemswith the OV6920; customer acceptance, demand, and the other risks detailedfrom time to time in OmniVision's Securities and Exchange Commission filingsand reports, including, but not limited to, OmniVision's annual reports filedon Form 10-K and quarterly reports filed on Form 10-Q. OmniVision expresslydisclaims any obligation to update information contained in any forward-looking statement.

Subscribe to our RSS Feeds